(CercleFinance.com) – Eli Lilly announced today that Zepbound (tirzepatide) injection is now available.
As a reminder, Zepbound is indicated for obese adults (i.e. whose BMI is equal to or greater than 30) or those who are overweight (BMI equal to or greater than 27) who also have weight-related medical problems (hypertension, dyslipidemia , type 2 diabetes, obstructive sleep apnea, cardiovascular diseases) and who wish to lose weight sustainably.
Following approval from the United States Food and Drug Administration (FDA) on November 8, 2023, people suffering from obesity can now access Zepbound in six doses (2.5 mg, 5 mg, 7.5 mg , 10 mg, 12.5 mg, 15 mg) by prescription.
‘Making Zepbound available in U.S. pharmacies is a first step, but now we must work hand-in-hand with employers, government and healthcare partners to remove barriers and make Zepbound accessible to those who have them need. We are excited to see growing coverage in the market, allowing millions of Americans to access Zepbound,’ commented Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on LILLY AND CO in real time: